US equities |
SPCX $144.75 ▼-9.14% MU $856.49 ▼-6.26% NVDA $212.21 ▼-4.40% META $648.85 ▼-6.98% TSLA $374.58 ▼-3.08% AAPL $348.22 ▲+1.23% AMD $507.93 ▼-8.10% SNDK $1,260.93 ▼-8.51%
FinancialContent

Articles published by TRex Bio, Inc.

News headline image
TRexBio Announces Closing of Initial Public Offering
From TRex Bio, Inc.
Via GlobeNewswire
Tickers TRXB
News headline image
TRexBio Announces Pricing of Initial Public Offering
From TRex Bio, Inc.
Via GlobeNewswire
News headline image
TRexBio Announces Positive Topline Results from First-in-Human Phase 1a Study of TRB-061, a TNFR2 Agonist in Clinical Development for Atopic Dermatitis
From TRex Bio, Inc.
Via Business Wire
News headline image
TRexBio Announces Pipeline Progress, Naming TRB-071 as a CD30 Agonist for Immune-Mediated Diseases and Advancement of Lilly-Partnered TRB-051
From TRex Bio, Inc.
Via Business Wire
News headline image
TRexBio to Present Late-Breaking Data at the Society for Investigative Dermatology (SID) Annual Meeting Supporting TNFR2 Agonism as a Therapeutic Strategy for Atopic Dermatitis
From TRex Bio, Inc.
Via Business Wire
News headline image
TRexBio Doses First Patient with Moderate-to-Severe Atopic Dermatitis in Phase 1b Clinical Trial of TRB-061, a TNFR2 Agonist
From TRex Bio, Inc.
Via Business Wire
News headline image
TRexBio Closes $50 Million Financing to Support a Growing Clinical-Stage Immunology Pipeline of Tissue-Targeted Treg Therapeutics
From TRex Bio, Inc.
Via Business Wire
News headline image
TRexBio to Participate in Upcoming Investor Conferences in September
From TRex Bio, Inc.
Via Business Wire
News headline image
TRexBio Doses First Participant in Phase 1 Trial of TRB-061, a Novel TNFR2 Agonist for Atopic Dermatitis and Other Inflammatory Diseases
From TRex Bio, Inc.
Via Business Wire
News headline image
TRexBio Expands Leadership Team with Appointments of Ariella Kelman, M.D., as Chief Medical Officer and Brandon Hants, MBA, as Chief Financial Officer
From TRex Bio, Inc.
Via Business Wire
News headline image
TRexBio Announces $84 Million Series B Financing to Advance Pipeline of First-in-Class Immunology Programs into Clinical Development
From TRex Bio, Inc.
Via Business Wire
News headline image
TRexBio Announces Collaboration Partner Lilly Has Initiated a Phase 1 Study of TRB-051 for Autoimmune and Inflammatory Diseases
From TRex Bio, Inc.
Via Business Wire
News headline image
TRexBio Announces a First Option Was Exercised by Partner under Immunology Discovery Collaboration
From TRex Bio, Inc.
Via Business Wire
News headline image
TRexBio Announces Development Candidate, TRB-061, a Novel TNFR2 Agonist for the Treatment of Inflammatory Diseases
From TRex Bio, Inc.
Via Business Wire
News headline image
TRexBio Announces Collaboration and License Agreement with Lilly to Develop and Commercialize Novel Therapies for Immune-Mediated Diseases
From TRex Bio, Inc.
Via Business Wire